<DOC>
	<DOC>NCT01390519</DOC>
	<brief_summary>This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib). The goal is to document the treatment algorithm of these patients in Norway and the efficacy and tolerability of AfinitorÂ® in a pure 2.line setting.</brief_summary>
	<brief_title>A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age &gt; 18 years Confirmed diagnosis of advanced renal cell cancer Progression on or after one VEGF TKI (e.g. sunitibin, sorafenib) Written informed consent Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>mRCC,</keyword>
	<keyword>observational,</keyword>
	<keyword>Afinitor,</keyword>
	<keyword>everolimus,</keyword>
	<keyword>2.line</keyword>
</DOC>